BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:33 PM
 | 
Oct 15, 2012
 |  BC Extra  |  Clinical News

Abbott adds $4.3B on HCV data

Abbott Laboratories (NYSE:ABT) added $4.3 billion in market cap on Monday after reporting data from the Phase IIb Aviator trial of an interferon-free regimen that includes three of Abbott's antivirals to treat HCV genotype 1 infection. The regimen --...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >